Patent ID: 8455492

Claim:
A method for treating a retinal disease selected from the group consisting of retinopathy, diabetic retinopathy, retinal ischemia, choroidal ischemia, retinal microvascular disease, retinal vascular occlusion, damaged retinal pigment epithelium, retinal neovascularization, retinitis piqmentosa and macular degeneration to a subject, the method comprising: administering to said subject in need thereof, intravitreally, a therapeutically effective amount of an alpha 2 adrenergic receptor agonist; wherein the alpha 2 adrenergic receptor agonist is a compound of the formula wherein the 2-imidazolin-2-ylamino group is in either the 5-or 6-position of the quinoxaline nucleus: x, y and z are in any of the remaining 5-, 6-, 7-or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either the 2-or 3-position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy, or pharmaceutically acceptable salts thereof and mixtures thereof.